EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study

Zhigong Wei, Huijiao Chen, Dejuan Wang, Leyu Li, Yiyan Pei, Huaju Yang, Feng Wang, Jing Jin, Yiqiao Luo, Fei Chen, Jun Liu, Xingchen Peng

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014100 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Zhigong Wei und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Afatinib, Squamous Cell Carcinoma of Head and Neck, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Postdoctor Research Fund of West China Hospital, Sichuan University, Yunnan Province Key Laboratory of Precision Diagnosis and Treatment for Thoracic Diseases, Sichuan Science and Technology Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While immune checkpoint inhibitor-based neoadjuvant therapy shows promise in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the optimal regimen has yet to be established. We report, for the first time, a neoadjuvant treatment that combines chemotherapy with dual blockade of the programmed cell death protein 1 and epidermal growth factor receptor pathways in LA-HNSCC.

Methods

In this single-arm phase 2 trial ( NCT05516589 ) conducted at a single academic center, patients with LA-HNSCC were enrolled and received two cycles of tislelizumab and TP chemotherapy (nab-paclitaxel and cisplatin), administered on day 1 of each 3-week cycle, along with afatinib during the interval between chemoimmunotherapy cycles, followed by surgical resection. The primary endpoint was the complete pathologic response (pCR) rate. Secondary endpoints included the major pathologic response (MPR) rate, objective response rate (ORR), event-free survival, overall survival (OS), and safety.

Results

A total of 40 patients were enrolled and received neoadjuvant treatment, 32 of whom proceeded to surgical resection; among these patients, the pCR rate was 40.6% (95% CI 23.7% to 59.4%). The ORR was 82.5% (95% CI 67.2% to 92.7%). The 1-year OS rate was 97.3% (95% CI 92.2% to 100%). The most common treatment-related adverse event (TRAE) of grade 3−4 was lymphopenia (5/40, 12.5%). No grade 5 TRAEs leading to death occurred, and no treatment-related surgical delays were observed. In the prespecified exploratory biomarker analysis, increased cytotoxic T lymphocytes and B cells in the tumor immune microenvironment may be associated with pCR/MPR. Neoadjuvant treatment induced a significant increase in the proportion of peripheral CD8+T cells, along with a reduction in B cells.

Conclusions

We report, for the first time, the promising efficacy and acceptable safety profile of neoadjuvant chemoimmunotherapy combined with afatinib in patients with LA-HNSCC. Neoadjuvant treatment potentially induced an immune-enhanced tumor microenvironment. Further evaluation in large-scale clinical trials with longer follow-up periods is needed. Trial registration number NCT05516589 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyAfatinibSquamous Cell Carcinoma of Head and NeckAntineoplastic Combined Chemotherapy ProtocolsHead and Neck NeoplasmsImmunotherapyHumansFemaleMaleMiddle AgedAgedPathologic Complete ResponseAdult

Stichwörter der Autor:innen

ChemotherapyEGFRHead and Neck CancerImmune Checkpoint InhibitorsNeoadjuvant

Substanzen

Afatinib

Autor:innen und Institutionen

  • Department of Biotherapy, West China Hospital of Sichuan University, Chengdu, China.
  • Nuclear Physics and Medical Research Key Laboratory of Sichuan Province, Chengdu, China.
  • Department of Pathology, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Otolaryngology-Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Otolaryngology-Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China pxx2014@163.com junliu@wchscu.edu.cn hxchenfei@163.com.
  • Head and Neck Surgical Center, West China Hospital of Sichuan University, Chengdu, China.

Förderung

  • Postdoctor Research Fund of West China Hospital, Sichuan University
  • Yunnan Province Key Laboratory of Precision Diagnosis and Treatment for Thoracic Diseases
  • Sichuan Science and Technology Program
  • Regional Innovation and Development Joint Fund Key Project of the National Natural Science Foundation of China
  • Institutional Joint Innovation Fund from Sichuan University and Nuclear Power Institute of China
  • International Science and Technology Cooperation Program of Chengdu Science and Technology Bureau
  • Ministry of Education University-Industry Collaborative Education Program
  • National Natural Sciences Foundation of China

Zitieren

APA

Wei, Z., Chen, H., Wang, D., Li, L., Pei, Y., Yang, H., Wang, F., Jin, J., Luo, Y., Chen, F., Liu, J., & Peng, X. (2026). Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014100

Vancouver

Wei Z, Chen H, Wang D, Li L, Pei Y, Yang H, et al. Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014100

BibTeX
@article{Wei2026,
  author = {Wei, Zhigong and Chen, Huijiao and Wang, Dejuan and Li, Leyu and Pei, Yiyan and Yang, Huaju and Wang, Feng and Jin, Jing and Luo, Yiqiao and Chen, Fei and Liu, Jun and Peng, Xingchen},
  title = {Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014100}
}
Kostenlos starten →